title: Experience after 100 patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
abstract: OBJECTIVE
  To investigate perioperative patient morbidity/mortality and outcome after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
  
  
  METHODS
  Of 150 patients 100 were treated with cytoreductive surgery and HIPEC and retrospectively analyzed. Clinical and postoperative follow-up data were evaluated. Body mass index (BMI), age and peritoneal carcinomatosis index (PCI) were chosen as selection criteria with regard to tumor-free survival and perioperative morbidity for this multimodal therapy.
  
  
  RESULTS
  CRS with HIPEC was successfully performed in 100 out of 150 patients. Fifty patients were excluded because of intraoperative contraindication. Median PCI was 17 (1-39). In 89% a radical resection (CC0/CC1) was achieved. One patient died postoperatively due to multiorgan failure. Neither PCI, age nor BMI was a risk factor for postoperative complications/outcome according to the DINDO classification. In 9% Re-CRS with HIPEC was performed during the follow-up period.
  
  
  CONCLUSIONS
  Patient selection remains the most important issue. Neither PCI, age nor BMI alone should be an exclusion criterion for this multimodal therapy.
authors.affiliation: Department of Surgery, University of Tübingen, Hoppe-Seyler-Strasse 3, D-72076 Tübingen, Germany. ingmar.koenigsrainer@med.uni-tuebingen.de
authors.forename: Ingmar
authors.initials: I
authors.lastname: Königsrainer
authors.forename: Derek
authors.initials: D
authors.lastname: Zieker
authors.forename: Jörg
authors.initials: J
authors.lastname: Glatzle
authors.forename: Olivia
authors.initials: O
authors.lastname: Lauk
authors.forename: Julia
authors.initials: J
authors.lastname: Klimek
authors.forename: Stephan
authors.initials: S
authors.lastname: Symons
authors.forename: Björn
authors.initials: B
authors.lastname: Brücher
authors.forename: Stefan
authors.initials: S
authors.lastname: Beckert
authors.forename: Alfred
authors.initials: A
authors.lastname: Königsrainer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D015992:Body Mass Index; D015179:Colorectal Neoplasms / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D007274:Injections, Intraperitoneal; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000628:therapy; D018579:Patient Selection; D010534:Peritoneal Neoplasms / Q000628:therapy*; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents